RECRUITING

A Study of Observation and Follow-up in People With Basal Cell Carcinoma

Talk to us

Conditions

Basal Cell CarcinomaMemorial Sloan Kettering Cancer Center21-007

Quick Navigation

Study Overview

This clinical trial focuses on testing the efficacy of different digital interventions to promote re-engagement in cancer-related long-term follow-up care for adolescent and young adult (AYA) survivors of childhood cancer.

Description

The purpose of this study is to find out more about how Basal Cell Carcimonas/BCCs grow and to learn more effective ways to monitor and treat these common cancers. This study will not provide any type of treatment for the participants' cancer; it is a 3-year observational study to monitor participants' cancer.

Official Title

Basal Cell Carcinoma Follow Up Study. A Prospective Study

Quick Facts

Study Start:2022-07-27
Study Completion:2025-07
Study Type:Not specified
Phase:Not Applicable
Enrollment:Not specified
Status:RECRUITING

Study ID

NCT05473507

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Ages Eligible for Study:18 Years
Sexes Eligible for Study:ALL
Accepts Healthy Volunteers:No
Standard Ages:ADULT, OLDER_ADULT
Inclusion CriteriaExclusion Criteria
  1. * Patients 18 years of age or older
  2. * Diagnosed with at least 1 BCC based on clinical, dermoscopy, RCM and OCT
  3. * Patients with BCCs that have a diameter smaller or equal to 1.5cm, allowing for 0.5cm growth before reaching the cutoff for stage 2 BCC, which would require removal of the BCC.
  4. * Patients with BCCs that have a depth smaller or equal to 0.6mm, to allow for tumor growth of 0.2mm before reaching the depth limitation of OCT imaging (0.8mm)
  5. * Treatment naiive lesions
  6. * Ability to sign informed consent
  1. * Immunosuppressed patients, such as those with a primary immunodeficiency caused by a genetic abnormality and a secondary immunodeficiency caused by AIDS, cancer, chemotherapy and other immunomodulating drugs, solid organ transplant recipitents, CLL, aspelenia, and pregnancy).
  2. * Patients with cancer genetic syndromes that increase risk of BCC (such as basal cell nevus syndrome, xeroderma pigmentosum, epidermolysis bulosa, oculocutaneous albinism, bazex-dupre-christol syndrome, rothmund-thomson syndrome, and epidermodysplasia verruciformis).
  3. * Patients with BCCs that are clinically suspected as high risk histopathologic subtypes, i.e. indented or sclerotic lesions that are suspected as morpheaform or infiltrative BCCs.
  4. * Patients with BCCs that have a diameter larger than 1.5cm\\
  5. * Patients with BCCs that have a depth greater than 0.6mm
  6. * Patients with BCCs in high risk locations, i.e. "H" area of the face. (is located in the mid-face at the site of the embryologic fusion plates and is generally believed to be associated with more aggressive skin cancers).
  7. * Patients with BCCs on locations that may compromise an organ function should the tumor enlarge (for example, eyelid).
  8. * Tumor located on a site that precludes attachment of the RCM device or inability to tolerate imaging procedure (i.e. remain relatively still for multiple short durations of 3- 4 minutes over a total time of 20-30 minutes)
  9. * Lesions that previously received therapeutic intervention
  10. * Inability to give informed consent

Contacts and Locations

Study Contact

Ashfaq Marghoob, MD
CONTACT
631-863-5116
marghooa@mskcc.org
Allan Halpern, MD
CONTACT
646-608-2301
halperna@mskcc.org

Principal Investigator

Ashfaq Marghoob, MD
PRINCIPAL_INVESTIGATOR
Memorial Sloan Kettering Cancer Center

Study Locations (Sites)

Memorial Sloan Kettering Cancer Center (All Protocol Activities)
New York, New York, 10065
United States

Collaborators and Investigators

Sponsor: Memorial Sloan Kettering Cancer Center

  • Ashfaq Marghoob, MD, PRINCIPAL_INVESTIGATOR, Memorial Sloan Kettering Cancer Center

Study Record Dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Registration Dates

Study Start Date2022-07-27
Study Completion Date2025-07

Study Record Updates

Study Start Date2022-07-27
Study Completion Date2025-07

Terms related to this study

Keywords Provided by Researchers

  • Basal Cell Carcinoma
  • Memorial Sloan Kettering Cancer Center
  • 21-007

Additional Relevant MeSH Terms

  • Basal Cell Carcinoma